Today's City Moves cover banking, the air sector and medical research. Take a look at these movers and shakers:
TSB Bank has appointed Paulina Beato as an independent non-executive director. Paulina is an experienced board director and adviser with significant international expertise across a range of different industries and governmental agencies. Paulina is passionate about competition, has been very active within financial regulation and was deeply involved in the privatisation and restructuring of the utilities sector in Spain. She will bring a wealth of skills to TSB Bank’s non-executive team, including experience of audit, risk and risk analytics, as well as extensive knowledge of banking and banking competition in Europe.
Fastjet, which offers low-cost flights in Africa, has appointed a new non-executive chairman, a non-executive director and a new chief financial officer to its board. Rashid Wally has been appointed as non-executive chairman with effect from 1 April. Rashid is currently the chairman and member of the audit committee of Mango Airlines. He will be stepping down from Mango to take over the role of chairman of Fastjet from Nico Bezuidenhout, Fastjet CEO, who was appointed interim chairman in November 2016. Peter Hyde has been appointed as a non-executive director and chairman of the audit committee with immediate effect. Peter brings extensive financial and UK corporate expertise to the board, having spent more than 30 years in the financial services industry including extensively covering the transport and aviation sectors as a research analyst. Fastjet has also appointed Michael Muller as the new chief financial officer. The former CFO, Lisa Mitchell will remain in her role until 30 April or shortly thereafter, to facilitate an orderly transition with Michael and to support the company’s relocation process. Michael has been with Fastjet since November 2016, working out of the company’s Johannesburg offices.
Hutchison China Medi
Hutchison China MediTech, also known as “Chi-Med”, has appointed Dr Weiguo Su as executive director and member of the technical committee with effect from today. Weiguo, aged 59, has been the executive vice president and chief scientific officer of the company since 2012. Weiguo has headed all drug discovery and research since he joined the company, including masterminding the company’s scientific strategy. Prior to joining Chi-Med in 2005, he spent 15 years with the US research and development department of Pfizer. This month, he was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association as one of the most influential drug R&D Leaders in China.
To appear in City Moves please email your career updates and pictures to email@example.com.